Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Latanoprost/netarsudil (Primary) ; Latanoprost; Netarsudil
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms Mercury 1
- Sponsors Aerie Pharmaceuticals
- 08 Aug 2017 According to an Aerie Pharmaceuticals media release, data from this study and Rocket 4 were also included in the Rhopressa™ NDA submission as supportive.
- 01 Aug 2017 Status changed from active, no longer recruiting to completed, according to an Aerie Pharmaceuticals media release.
- 19 Jul 2017 Twelve month topline safety results published in an Aerie Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History